Compare FBRX & ZKH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FBRX | ZKH |
|---|---|---|
| Founded | N/A | 1998 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 487.2M | 484.8M |
| IPO Year | 2017 | 2022 |
| Metric | FBRX | ZKH |
|---|---|---|
| Price | $21.06 | $2.22 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $67.00 | N/A |
| AVG Volume (30 Days) | ★ 369.5K | 96.2K |
| Earning Date | 05-14-2026 | 05-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 61.30 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $36,000.00 | N/A |
| Revenue This Year | N/A | $9.02 |
| Revenue Next Year | N/A | $10.41 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $9.12 | $2.20 |
| 52 Week High | $35.80 | $3.90 |
| Indicator | FBRX | ZKH |
|---|---|---|
| Relative Strength Index (RSI) | 58.78 | 31.86 |
| Support Level | $16.58 | $2.20 |
| Resistance Level | $22.84 | $3.04 |
| Average True Range (ATR) | 1.40 | 0.15 |
| MACD | 0.77 | -0.04 |
| Stochastic Oscillator | 81.45 | 6.76 |
Forte Biosciences Inc is a clinical-stage biopharmaceutical company that is advancing through preclinical trials its product candidate, FB-102, which is a proprietary anti-CD122 monoclonal antibody therapeutic candidate with potentially broad autoimmune and autoimmune-related indications. The Company is also advancing clinical development of FB102 in patient-based trials for non-segmental vitiligo and alopecia areata.
ZKH Group Ltd engages in providing MRO procurement service platform in China. It provides one-stop MRO procurement and management services for its customers, and offers digital and fulfillment solutions for participants along the industry value chain. It offers a broad range of MRO product offerings covering all MRO product lines on its platform, including spare parts, chemicals, manufacturing parts, general consumables, and office supplies. All of the Group's revenues are derived from the PRC.